Topics
PSMO 36TH ANNUAL CONVENTION
Bringing Pfizer’s Legacy in Cancer Treatment to Biosimilars
PSMO 20TH MIDYEAR CONVENTION
Current Evidence of CDK4/6 Inhibitors in Breast Cancer Management
PSMO 20TH MIDYEAR CONVENTION
Switch from Biological to Biosimilar: Efficacy and Safety Evidences of Rituximab Biosimilar
PSMO 20TH MIDYEAR CONVENTION
Real world patient experience with PARP inhibitor, Olaparib in BRCA-mutated and non- BRCA mutated Ovarian Cancer
PSMO 20TH MIDYEAR CONVENTION
All about Innovation